Analysed SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS) News Sources
A Look At Sumitomo Pharma’s Valuation As AMCHEPRY Faces Key Japanese Regulatory Milestone
24-02-2026
yahoo.com
Sumitomo Pharma America Announces that its Investigational Therapy DSP-3077 Has Received FDA Orphan Drug Designation for the Treatment of Retinitis Pigmentosa
23-03-2026
yahoo.com
Assessing Sumitomo Pharma (TSE:4506) Valuation After A Strong Year And Recent Share Price Pullback
06-05-2026
yahoo.com
Japan Regenerative Medicine Market Trends and Forecasts to 2035 Featuring Astellas Pharma, Fujifilm, JCR Pharmaceuticals, Sumitomo Pharma, Takeda, and Terumo
13-05-2026
yahoo.com
Generalized Anxiety Disorder Market Forecast Shows Strong CAGR During the Forecast Period (2026-2036) Driven by Innovative Therapies | DelveInsight
04-06-2026
yahoo.com
Sumitomo Pharma America Announces Enzomenib (DSP-5336) Receives FDA Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia
30-07-2026
yahoo.com
What is the current price of SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS)?
The current price of SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS) is $8.405.
SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS) since the previous trading day is $-1.005.
SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS) since the previous trading day is -10.6801%.
What is the most recent average sentiment score for SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS)?
The most recent average sentiment score for SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS) is 50 out of 100.
What is the most recent average sentiment for SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS)?
The most recent sentiment for SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS) is .
SEC-8K** Filing Available For SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.